A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA
Lay Description
Category
- Aging and Geriatric
- Mens Health
- IRB Number
- 20220801HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Sarah Martinez
210-450-0569
martinezs23@uthscsa.edu
Charlotte Rhodes
210-450-8454
rhodesc1@uthscsa.edu
Principal Investigator
Reza Behrouz